Journal Article

T1653 Mutation in the Box a Increases the Riskof Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Genotype C Infection

Kiyoaki Ito, Yasuhito Tanaka, Etsuro Orito, Masaya Sugiyama, Kei Fujiwara, Fuminaka Sugauchi, Takanobu Kato, Hajime Tokita, Namiki Izumi, Michio Kato, Man-Fung Yuen, Ching-Lung Lai, Robert G. Gish, Ryuzo Ueda and Masashi Mizokami

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 42, issue 1, pages 1-7
Published in print January 2006 | ISSN: 1058-4838
Published online January 2006 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/498522
T1653 Mutation in the Box a Increases the Riskof Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Genotype C Infection

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

Most patients with chronic hepatitis B virus infection become carriers of inactive virus after hepatitis B e antigen seroconversion; however, a subgroup of patients have persistent abnormal transaminase levels and develop hepatocellular carcinoma after seroconversion.

In an age-matched case-control study, 40 carriers of inactive virus (mean age ± standard deviation [SD], 50.9 ± 11.1 years), 40 patients with chronic hepatitis (mean age ± SD, 50.2 ± 8.9 years), and 40 patients with hepatocellular carcinoma (mean age ± SD, 50.7 ± 9.4 years) who were infected with hepatitis B virus genotype C and had test results positive for antibody to hepatitis B e antigen were analyzed.

The prevalence of T1653 in the box α was significantly higher among patients with hepatocellular carcinoma than among carriers of inactive virus who did not have hepatocellular carcinoma (70% vs. 25%; P <.0001) or chronic hepatitis (70% vs. 35%; P =.003). Mutations in the basic core promoter region (T1762/A1764) were frequently found in all groups, regardless of clinical status (in 77.5% of carriers of inactive virus, 77.5% of patients with chronic hepatitis, and 90% of patients with hepatocellular carcinoma). In the multivariate analysis, the presence of T1653, an alanine aminotransferase level of ⩾ 37 U/L, and a platelet count of <18 × 104 platelets/mm3 were independent predictive values for hepatocellular carcinoma (odds ratio [95% confidence interval], 5.05 [1.56–16.35], 12.56 [3.05–51.77], and 11.5 [3.47–38.21], respectively). High α -fetoprotein level was the only independent predictive value for T1653 in patients with hepatocellular carcinoma (odds ratio, 12.67; 95% confidence interval, 1.19–134.17]). Among patients with test results positive for antibody to hepatitis B e antigen who had hepatocellular carcinoma and were infected with different genotypes of hepatitis B virus, the prevalence of T1653 was 40%, 15%, 25%, 25%, 67%, and 23% in patients infected with hepatitis B virus genotypes Aa, Ae, Ba, Bj, C, and D, respectively (P <.05 for genotype C vs. genotypes Ae, Ba, Bj, or D).

Our data indicate that the addition of T1653 mutation in the box α to the basic core promoter mutation increases the risk of hepatocellular carcinoma in patients with hepatitis B virus genotype C.

Journal Article.  3505 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.